Consun Pharmaceutical Group Ltd. Prepares for Annual General Meeting

Consun Pharmaceutical Group Ltd. (Hong Kong Stock Exchange: 01681) has issued a series of formal notifications to its shareholders, signalling the upcoming Annual General Meeting (AGM) scheduled for the latter part of April 2026. The company has dispatched a notification letter, a proxy form, a meeting notice, and a detailed agenda outlining key proposals that will be voted upon during the session.

Key Documents and Timing

The sequence of announcements, all released between 22:37 and 22:42 UTC on 27 April 2026, follows the regulatory requirements for disclosure under Hong Kong exchange rules. The documents are hosted on the Hong Kong Exchanges and Clearing (HKEX) news portal (www1.hkexnews.hk). Investors and interested parties can access the following:

  • Notification Letter to Shareholders – Provides an overview of the AGM, confirming the date, time, and venue, and invites shareholders to participate.
  • Form of Proxy for the AGM – Allows shareholders who cannot attend in person to appoint a proxy to vote on their behalf.
  • Notice of AGM – Sets forth the procedural details, including how to register for the meeting and the logistics for attendance.
  • Full Agenda and Proposals – Lists the items on the ballot, including:
  1. Re‑election of retiring directors.
  2. Proposal of a final dividend for the fiscal year.
  3. Re‑appointment of the external auditor.
  4. Additional items (the agenda references further proposals, though specifics are not disclosed in the provided excerpt).

Corporate Context

Consun Pharmaceutical Group Ltd. is a Guangzhou‑based pharmaceutical entity operating within China’s health‑care sector, with a focus on modern Chinese medicines and medical contrast media. The company’s shares were last quoted at HKD 15.84 on 23 April 2026, trading within a 52‑week range of HKD 9.23 to HKD 19.35. With a market capitalisation of approximately HKD 13.33 billion and a price‑earnings ratio of 10.83, the firm sits comfortably in the mid‑cap segment of the market.

What to Expect

The AGM will likely address standard governance matters. The re‑election of directors is a routine procedure, yet it offers shareholders a chance to affirm or change leadership. The dividend proposal will reflect the company’s profitability and cash‑flow situation; the final dividend amount will be disclosed during the meeting. The re‑appointment of the auditor underscores Consun’s commitment to maintaining transparent financial reporting practices.

Shareholders who wish to participate directly or through a proxy should consult the proxy form and AGM notice for detailed instructions. The Hong Kong Exchanges and Clearing platform provides the necessary forms and voting guidelines to ensure a smooth and compliant process.

By adhering to regulatory transparency and engaging its investor base, Consun Pharmaceutical Group Ltd. demonstrates its ongoing dedication to robust corporate governance and shareholder value.